Andrisha-jade Inderjeeth
Nedlands, WA, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
SUBDUE-3: SUB-urothelial DUrvalumab-89zirconium injEction; a phase 0 biodistribution study protocol.
SUBDUE-3: SUB-urothelial DUrvalumab-89zirconium injEction; a phase 0 biodistribution study protocol.
Journal: BJU international
Published: February 12, 2026
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304).
Journal: European urology oncology
Published: November 10, 2025
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Journal: Future oncology (London, England)
Published: January 17, 2025
Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study.
Journal: Clinical genitourinary cancer
Published: December 03, 2024
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 29, 2024
Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors.
Journal: JCO oncology practice
Published: May 28, 2024
Corrigendum to 'Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review [European Journal of Cancer 184 (2023) 83-105].
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 01, 2023
Novel radionuclide therapy combinations in prostate cancer.
Journal: Therapeutic advances in medical oncology
Published: February 27, 2023
Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 15, 2022
Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
Journal: Cancers
Published: November 02, 2022
Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management.
Journal: Frontiers in immunology
Published: September 20, 2022
Noninvasive Diagnosis of Irritable Bowel Syndrome via Bowel Sound Features: Proof of Concept.
Journal: Clinical and translational gastroenterology
Published: March 26, 2019
Last Updated: 09/26/2026